Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 31:3:100100.
doi: 10.1016/j.hctj.2025.100100. eCollection 2025.

Clinical trials and young adults with inflammatory bowel disease

Sneha Dave  1   2 , Sydney Reed  1   2 , Mara Shapiro  1   2   3 , Yeabsira Taye  2 , Isabela Hernandez  1   2   4 , Navin Kariyawasam  2   5   6 , Ildiko Mehes  7   8 , Manasi Agrawal  9 , Miguel Regueiro  10 , Adam Faye  2   11 , Jeremy Adler  12   13
Affiliations

Clinical trials and young adults with inflammatory bowel disease

Sneha Dave et al. Health Care Transit. .

Abstract

Young adults (approximately 18-35 years) with inflammatory bowel disease (IBD) represent a distinct demographic with unique developmental and physiological characteristics, yet they are underrepresented in clinical trials. This commentary synthesizes insights from a roundtable discussion facilitated by the Crohn's and Colitis Young Adults Network (CCYAN) between young adult patients with IBD and medical professionals, including physicians, nurses, psychologists, and trainees/medical students. Themes include defining young adults as a distinct demographic in research, improving outcomes for young adults with IBD through age-specific data disaggregation, barriers for participation and post-trial responsibilities, as well as regulatory and legislative policy opportunities to enhance young adult representation in clinical trials.

Keywords: Adolescents in clinical trials; Clinical trial diversity; Young adults in clinical trials; Young adults with inflammatory bowel disease.

PubMed Disclaimer

Conflict of interest statement

The authors do not have conflicts of interest.

References

    1. Ha C., Ullman T.A., Siegel C.A., Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10(9):1002–1007. 〈https://www.sciencedirect.com/science/article/abs/pii/S1542356512002017〉 - PubMed
    1. Atia O., Pujol-Muncunill G., Navas-López V.M., et al. Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix. Aliment Pharmacol Ther. 2022;56(5):794–801. 〈https://onlinelibrary.wiley.com/doi/abs/10.1111/apt.17092〉 - DOI - PMC - PubMed
    1. Agrawal M., Christensen H.S., Bøgsted M., Colombel J.F., Jess T., Allin K.H. The rising burden of inflammatory bowel disease in Denmark over two decades: a nationwide cohort study. Gastroenterology. 2022;163(6):1547–1554. 〈https://www.sciencedirect.com/science/article/pii/S0016508522008812〉 e5. - PMC - PubMed
    1. Johnson C., Barnes E.L., Zhang X., Long M.D. Trends and characteristics of clinical trials participation for inflammatory bowel disease in the United States: a report from IBD partners. Crohn’s Colitis. 2020;360(2):2. 〈https://academic.oup.com/crohnscolitis360/article-abstract/2/2/otaa023/... - PMC - PubMed
    1. International Council for Harmonisation (ICH) ICH E11(R1) Guideline on Clinical Investigation of Medicinal Products in the Pediatric Population: Addendum. European Medicines Agency; 2017. 〈https://www.ema.europa.eu〉

LinkOut - more resources